Disease Focused

These include focused libraries of small-molecule compounds with potential biological activity towards certain diseases (such as Anti-Cancer Compound Library, Anti-Diabetic Compound Library, Anti-Cardiovascular Disease Compound Library, etc.).

Cat No.	product name
L2100	Anti-cancer Compound Library	A unique collection of 3338 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);	3338 compounds
L1900	Anti-diabetic Compound Library	A unique collection of 179 diabetes related compounds;	179 compounds
L1800	Anti-infection Compound Library	A unique collection of 605 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc;	605 compounds
L1700	Anti-virus Compound Library	Quantity: A unique collection of 456 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;	456 compounds
L4700	Immunology/Inflammation Compound Library	A unique collection of 876 anti-inflammation compounds effective for high throughput screening and high content screening.	876 compounds
L4500	Antifungal Compound Library	A unique collection of 66 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation.	66 compounds
L2110	Anti-cancer Approved drug Library	A unique collection of 330 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);	330 compounds
L2120	Anti-cancer Clinical Compound Library	A unique collection of 594 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);	594 compounds
L5200	Anti-Metabolism Disease Compound Library	A unique collection of 1040 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);	1040 compounds
L5400	Anti-Cardiovascular Disease Compound Library	A unique collection of 515 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);	515 compounds
L2130	Anti-cancer Metabolism Compound Library	A unique collection of 237 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);	237 compounds
L2140	Promoting Cancer Cell Differentiation Compound Library	A unique collection of 251 cancer cell differentiation inducing compounds for high throughput and high content screening;	251 compounds
L7100	Anti-obesity Compound Library	A unique collection of 755 anti-obesity compounds for high throughput and high content screening;	755 compounds
L8400	Hematonosis Compound Library	A unique collection of 126 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);	126 compounds
L2160	Anti-cancer Active Compound library	A unique collection of 1164 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);	1164 compounds
L2150	Anti-cancer Drug library	A unique collection of 822 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);	727 compounds
L4510	Anti-Parasite Library	Quantity: 358 well-chosen unique anti-parasitic small molecules;	358 compounds
L4520	Antibacterial Activity Library	A unique collection of 909 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;	909 compounds
L4660	Nervous system disease Library	Quantity: well-chosen 935 compounds with unique structures targeting nervous system;	935 compounds
L2180	Anticancer Library Plus	Quantity: well-chosen 958 anti-tumor compounds with unique structures;	958 compounds
L2170	Small Molecule Immuno-Oncology Compound Library	A unique collection of 235 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；	235 compounds
L1710	Anti-COVID-19 Compound Library	A unique collection of 2448 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents；	2448 compounds
L1711	Anti-COVID-19 compound library (CADD)	A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	362 compounds
L1712	3CLpro-Targeted compound library (CADD)	A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	161 compounds
L1713	ACE2-Targeted compound library (CADD)	A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	462 compounds
L1714	RBD-Targeted compound library (CADD)	A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	206 compounds
L1715	nsp16-Targeted compound library (CADD)	A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	281 compounds
L1716	PLpro-Targeted compound library (CADD)	A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	474 compounds
L1717	RdRP-Targeted compound library (CADD)	A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	464 compounds
L1718	X Domain-Targeted compound library (CADD)	A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	463 compounds
L1719	nsp15-Targeted compound library (CADD)	A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	470 compounds
L2620	Neurodegenerative disease-related Compound Library	A unique collection of 527 compounds related to neurodegenerative diseases can be used for HTS or HCS；	527 compounds
L2190	Anti-Lung Cancer Compound Library	A unique collection of 400 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；	400 compounds
L4710	Nonsteroidal Antiinflammatory Compound Library	530 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.	530 compounds
L2191	Anti-Breast Cancer Compound Library		926 compounds
L2192	Anti-Pancreatic Cancer Compound Library		788 compounds